Atlanta, GA -- June 11, 2019 -- InvestorsHub NewsWire -- via Emerging MicroCaps -- 

  • Last year, US Nuclear shares (now $1.00) spiked to $5 when they announced an exclusive partnership with MIFTEC and a revolutionary new way to make and supply billions of dollars of medical radioisotopes at half today's cost to a $10 Billion industry that is suffering from severe shortages and high costs.

 

  • Powerful neutron flux is required to produce radioisotopes and 50-year-old, unreliable, costly and hazardous fission reactors have been the primary source of neutron flux.

 

  • Recently, the leading Fusion Energy Science Journal, peer reviewed, investigated, verified, and reported US Nuclear's partner MIFTEC, achieved major milestone of 1010 neutron flux from fusion power at UNR TeraWatt Facility proving that their radical new fusion technology works exactly as predicted and can make billions of dollars of high-quality radioisotopes for half the current cost.

 

  • MIFTEC hired a leading nuclear fusion design engineer from a National Lab and has already completed design plans for the first commercial 10 Mega Ampere LTD-X (linear transformer driver) Staged Z-Pinch Fusion Generator that can be built in between 1 and 2 years, and US Nuclear is now looking for locations to build MIFTEC's Fusion Generators.

 

  • US Nuclear is highly respected provider of technical products to the military and other demanding customers and enjoys strong growth and potential for strong price appreciation. Only 17 million shares outstanding of which about 10 million are closely held by management.

 

  • When news about this discovery was announced last year, US Nuclear shares spiked to $5 per share. Now that their multi-billion-dollar discovery has been confirmed by the leading fusion energy journal, and their machine is ready to be built, shares are highly undervalued with potential to soon shatter previous highs by several multiples.


Overview

Medical radioisotopes are essential for accurately diagnosing cancer and heart disease and for treating about half of all cancers.

Unfortunately for cancer and heart patients, a multi-billion-dollar annual shortage of radioisotopes is predicted to worsen because over 90% of radioisotopes are made in only 5 nuclear fission reactors that are unreliable because they are about 50 years old and subject to frequent unpredictable shutdowns. These 5 nuclear reactors are all outside the United States and not practical owing to the very short life of around 6 hours for the isotopes and the time-consuming distances they must travel to get to the end user.  Additionally, these nuclear fission reactors cost billions of dollars to replicate, they can take over a decade to build, they require radioactive uranium as fuel that is extremely hazardous and that requires very costly handling and disposal.

To help ease the shortage, there is a current effort underway to build smaller and cheaper reactors in the United States using Low Enriched Uranium, but the extremely high cost of disposing of any high enriched uranium or low enriched uranium will continue to perpetuate high prices and it will still take several years for these smaller reactors to come on line. Some of the better known competitors using the new twist of Low Enriched Uranium that is still the same old costly and hazardous fission technology are Northstar, Shine, Niowave, and Northwest Medical.  In fact, it is likely that the use of LEU will be even more expensive than HEU because of the more frequent handling and disposal.

In spite of all efforts, the shortage is predicted to last until a revolutionary technical breakthrough is discovered to be able to make radioisotopes from some other lower cost and safer source.


How radioisotopes are made

While a small number of radioisotopes occur naturally, by far the greatest percentage is made from neutrons that are produced in nuclear fission reactors.  Cyclotrons and particle accelerators also produce neutrons but only in very small quantities that are not practical.

Any powerful source of neutrons can be used to produce radioisotopes.

US Nuclear Corp's (OTC: UCLE) exclusive partner, MIFTEC/MIFTI (Magneto Inertial Fusion Technologies) Achieves Revolutionary Breakthrough

Recently, the leading Fusion Energy Science Journal reported that MIFTI/MIFTEC technology achieved 1010 power in neutron flux at the University of Nevada, Reno Terawatt Facility (UNR/NTF) in experiments using a 1 Mega Ampere machine. Results were confirmed by an independent laboratory. This is a feat never before accomplished by a privately held company in the history of fusion science. These important results were peer reviewed, investigated for confirmation, and published in Physics of Plasmas May 2019 issue.

Because the current flow of 1 Mega Ampere limited neutron production to close to 1010 on the UNR machine, MIFTI/MIFTEC quickly moved forward and already completed design plans for a larger 10 Mega Ampere machine that is predicted to generate 1015 in neutrons that is well in excess of the 1012 required for the production of radioisotopes. US Nuclear has already announced that they are now searching for the best cities to build their new generators.

US Nuclear, MIFTI and MIFTEC agree that a conservative estimate for the time to build the first commercial generator will probably take less than 24 months, but are giving themselves extra time for potential delays that are unknown. The companies are weighing various locations and funding options and once they have made a decision leading to completion of funding and location for the first machine, construction will commence.

Why UCLE and MIFTEC will dominate the $10 Billion Medical Radioisotope Industry

  • Most importantly because UCLE/MIFTEC will be able to deliver the highest quality medical radioisotopes in enormous quantities at HALF PRICE!
  • The LTD-X Staged Z-Pinch Fusion Generator will be very low cost to build and operate compared to all other competition.
  • The LTD-X Staged Z-Pinch Fusion Generator is very small and can fit in a hospital or medical center where the Radioisotopes will be used.
  • No long-term hazardous nuclear waste.

When asked what the biggest milestone achievements have been since they first announced their breakthrough technology last year, Jerry Simmons said, "In the second half of last year we did what nobody else has ever been able to do. Not even the big government projects. We made history by generating Neutron Flux in excess of 1010 from fusion power using an isotope of hydrogen from seawater instead of radioactive enriched uranium. This proves beyond any doubt that our machine can make the isotopes used in nuclear medicine (i.e. Mo-99, Tc-99m, cobalt 60, iodine, etc.). It is only a matter now of simply scaling the power or electric current flow of our machine up so we can achieve the greater Neutron Flux of 1012+. Dr. Hafiz Rahman, President and Chief Scientist and his staff at MIFTEC Labs and the University of Nevada, Reno National Terawatt Facility, tells us that our scientific experimental predictions and the device will work as designed."

  

Dr. Hafiz Rahman says, "To give you an idea of how advanced we are, when we achieve 1015, it will be 10,000,000,000 (ten billion) times more powerful than 105. That is more than enough power to create all the Neutron Flux we need to supply low cost radioisotopes and power for production of electricity with our compact, low cost machines."

 

Simmons continuing, "The machine we used at University of Nevada, Reno National Terawatt Facility was a 1 MA (1 Mega Amp) machine which limited the Neutron Flux we could generate to 1010. Last year, we hired a top nuclear design engineer and he has already completed the design for our new 10 MA (10 Mega Amps) LTD-X Staged Z-Pinch Fusion Generator that is designed to generate 1015 Neutron Flux that is extremely powerful and matches or exceeds the high power of the fission reactors being used today for radioisotope production. Our new generators are small and will fit into a building close to where the radioisotopes will be used. Our generators will be only a tiny fraction of the cost of the huge nuclear fission reactors and linear accelerators, and there will be no long-term hazardous radioactive waste to contend with that is dangerous and extremely expensive. Nuclear fission reactors can cost anywhere from several hundred million dollars to several billion dollars and we estimate that our machine will sell for around 5 million dollars. Our Staged Z-Pinch LTD-X Fusion Generator will be small and compact and will require very few people to operate. The bottom line is that we will be able to deliver enormous amounts of high-quality radioisotopes for about half today's cost."

 

About Bob Goldstein and Jerry Simmons

Bob Goldstein, the CEO of US Nuclear, graduated from MIT with a degree in Physics and has a degree in Engineering from Stanford. He has authored more than 40 white papers and presentations on radiation measurement and his work has been met and approved by US Federal standards set by the EPA, FDA, and NRC. He also works closely with Los Alamos, Sandia and Jefferson National Labs. His family's first experiences in nuclear physics go back to the 1940's when his father was involved in the historic Manhattan Project that developed the atomic bomb.

 

Mr. Goldstein founded US Nuclear and is known for delivering the most sensitive, accurate and reliable instruments in the world. The quality of their work is confirmed by a list of loyal and repeat customers such as NASA, the EPA, Department of Energy, U.S. Air Force, U.S. Army, U.S. Navy, MIT, Pacific Gas & Electric, General Electric, Lawrence Livermore, Oakridge National Lab and many more.

 

Jerry Simmons is the only person in the world who has founded two fusion energy companies. In 1998, Mr. Simmons co-founded Tri-Alpha Energy that is a now a multi-billion-dollar company with big early investors such as Paul Allen's Vulcan Investments and Art Samburg's hedge fund. The company is now called TAE Technologies. Jerry also co-founded Magneto-Internal Fusion Technologies, Inc. (MIFTI) and MIFTEC Laboratories, Inc. Mr. Simmons is very experienced and well connected with government officials that are interested in nuclear fusion based power and radioisotopes that are produced from fusion power sources. Mr. Simmons has negotiated a work package between MIFTEC Laboratories and Oak Ridge National Laboratory.

 

About US Nuclear

US Nuclear has enjoyed a long-standing financial history of stable sales and profitability, but in 2017 demand for US Nuclear's products began increasing and has continued at a high growth rate since. Several new large opportunities are blossoming in the underserved radioisotope market, and the environmental monitoring market that is forecast to hit $20 billion by 2021. For example, China is converting all of their coal-fired power plants that are responsible for dangerous polluted air and water, to about 200 fission nuclear reactors that all require the best radiation monitoring equipment in order to insure safety. The Chinese nuclear agency claims that each individual nuclear power plant requires about $8,000,000 in the highest quality and most reliable radiation monitoring devices and has already met with Mr. Goldstein twice last year with the intention of purchasing large orders of US Nuclear monitoring equipment. With World Nuclear Power Organization's forecast for a growing number of nuclear power plants to produce electricity (none planned to produce radioisotopes), the demand for radiation monitoring devices also grows.

 

Other large opportunities for US Nuclear are their unique products recently offered for radon mitigation in homes and offices and the use of drones to mount their sophisticated monitoring devices. Radon is commonly found in many homes and is one of the leading known causes of lung cancer. Goldman Sachs sees the drone market growing to a very large size by 2020. Drones are the perfect vehicle for carrying US Nuclear environmental monitoring devices for public safety and for national security threats of terrorism that could impact our air or water.

 

In conclusion, US Nuclear is enjoying strong growth from its core business, and on top of that, is well positioned to become a major supplier in a multi-billion-dollar healthcare market of radioisotopes.

 

Goldstein says, "Given the failing state of essential medical isotope production facilities, this first-ever achievement to meet and exceed the 1010 milestone in fusion neutron production could not come at a better time. Additionally, the projected cost savings of up to 50% over the current imported resources; the idea of on-site production; the low cost and shorter time to build the generators, and the environmental benefit of a non-proliferating process that precludes the hazards of fission-based methods; should make for important upgrades ahead in the vital medical isotope supply chain."

 

Conclusion

US Nuclear reports only 17 million shares outstanding translating to a very small market cap of about $20 million. Of the 17 million shares outstanding, management owns about ten million shares. The float is small and based on a number of metrics including sales, the share price is substantially undervalued. Any investor looking at US Nuclear should run the numbers for themselves and calculate what the shares could be valued at if their sales mushroomed to the large numbers that the radioisotope business can bring. The big question is, "How much of a $10 Billion-dollar market (that is expected to be $17 Billion in 2021), can US Nuclear and MIFTEC own if they can deliver valuable, high demand radioisotopes at half-price? And if US Nuclear generates billion dollar sales with only 17 million shares outstanding, how high will the price go?   With the best science, the best solution, and the capability to deliver high quality radioisotopes at half the current cost, it seems likely that UCLE and MIFTEC can capture at least 50% of the $7 billion shortage and a similar amount of the $10 billion supply.  Running the numbers suggests very lofty prices.

 

US Nuclear shares appear to be a bargain and poised for record highs in the not too distant future.

 

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging MicroCaps or its principals may have been compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as ''expects,'' ''will,'' ''anticipates,'' and ''estimates''; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements.

June 11, 2019

Emerging MicroCaps

Atlanta, GA

EmergingMicroCaps.com

US Nuclear Corp. (UCLE)

 

US Nuclear (QB) (USOTC:UCLE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more US Nuclear (QB) Charts.
US Nuclear (QB) (USOTC:UCLE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more US Nuclear (QB) Charts.